Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Incyte Corporation (INCY) — XLV Health Care · S&P 500 Profile |Incyte 公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Incyte Corporation (INCY) — Business, History & S&P 500 Profile | Incyte 公司介紹

Incyte Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #367 · Incyte 業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 4, 2026
Financials: FY2025
MARKET CAP
$23.97B
Nov 4, 2026
S&P 500 WEIGHT
0.03%
Rank #367 · Nov 4, 2026
SECTOR RANK
#46
Health Care · Nov 4, 2026
S&P 500 RANK
#367
0.03% · Nov 4, 2026

SNAPSHOT

TickerINCY
CompanyIncyte Corporation
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#367 · 0.03% (Nov 4, 2026)
Sector rank#46 of 60 in Health Care (Nov 4, 2026)
HeadquartersWilmington, Delaware
Founded1991
CEOBill Meury (President and CEO, per February 2026 results release)
Employees2,844 full-time employees
Market cap$23.97B (Nov 4, 2026)
SEC filingsEDGAR — CIK 0000879169

WHAT IT DOES

Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, focused on hematology and oncology plus inflammation and autoimmunity. Founded in 1991, it discovers, develops and commercializes proprietary therapeutics, selling in the United States, Europe and Japan through its own operations and partnerships including Novartis and Eli Lilly.

Its one-line model: turn JAK-pathway and targeted science into marketed medicines, then reinvest product cash flow into a pipeline spanning hematology, oncology and dermatology. The flagship is Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera and graft-versus-host disease; the growth engine is the non-Jakafi portfolio led by Opzelura (ruxolitinib) cream.

Fiscal 2025 total revenue was $5.14B, up 21%, of which net product revenue was $4.35B, up 20%. The non-Jakafi core grew 53% to $1.26B in 2025, with Opzelura, Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease and Monjuvi (tafasitamab) among the largest contributors.

BUSINESS SEGMENTS

Jakafi (ruxolitinib)Flagship JAK inhibitor for myelofibrosis, polycythemia vera and graft-versus-host disease; partnered with Novartis outside the United States and the largest single product.
Opzelura (ruxolitinib) creamTopical JAK inhibitor for atopic dermatitis and vitiligo; a core driver of the non-Jakafi growth story, including a U.S. approval for pediatric eczema patients aged 2–11.
Other Hematology / OncologyNiktimvo in chronic graft-versus-host disease, Monjuvi in relapsed or refractory diffuse large B-cell lymphoma, plus Pemazyre and Iclusig; together with Opzelura, the ex-Jakafi core reached $1.26B in 2025, up 53%.
Milestones, royalties & other revenueCollaboration milestones and contract revenue plus royalties — the difference between $5.14B total revenue and $4.35B net product revenue in 2025.

HISTORY

YearMilestone
1991Incyte is founded in Wilmington, Delaware, as a drug-discovery company.
2011Jakafi becomes the anchor product of the company (ruxolitinib, developed with Novartis as partner outside the United States).
2014Hervé Hoppenot serves as chief executive from 2014, leading the Jakafi commercial era.
2021Opzelura cream launches, opening the dermatology franchise alongside hematology and oncology.
2025Total revenue reaches $5.14B, up 21%; non-Jakafi products grow 53% to $1.26B, and Bill Meury is president and CEO in the February 2026 results release.

COMPETITIVE POSITION

  • Jakafi depth: a large, durable U.S. franchise in rare blood cancers, with prescribing growth still in high single digits in 2025 guidance commentary.
  • Diversification in motion: the ex-Jakafi core grew 53% in 2025 and is guided to grow over 30% in 2026, reducing single-product dependence ahead of the Jakafi patent horizon.
  • Partnership leverage: Novartis (Jakafi ex-U.S.), Lilly and others extend reach without a full global commercial build.
  • Competition set: large hematology and oncology players and dermatology rivals, plus generics at the patent cliff.

FINANCIAL SNAPSHOT

Total revenue$5.14B (FY2025 total revenue)
Operating income$1.51B (FY2025 operating income)
Net income$1.29B (FY2025 net income)
Diluted EPS$6.59 (FY2025 diluted EPS)
Source: Incyte Corporation fiscal 2025 Form 10-K (year ended December 31, 2025, filed February 10, 2026) and fourth-quarter/full-year 2025 results release; exact figures: total revenue $5,141M; operating income $1,514.9M; net income $1,287M; diluted EPS $6.59; net product revenue $4,352M approx. ($4.35B as reported). Fiscal 2024 comparatives: total revenue $4,241M; net income $33M; diluted EPS $0.16.

KEY RISKS

  • Jakafi concentration and patent horizon: the flagship faces patent expiration in 2028, and diversification must scale before generics arrive.
  • Pipeline risk: clinical, regulatory and commercial execution across hematology, oncology and dermatology candidates.
  • Pricing and payer pressure: specialty-drug pricing, gross-to-net dynamics and formulary access affect realised revenue.
  • Single-product read-throughs: Jakafi demand, competition or safety signals still move the group.
  • M&A and capital allocation: deals such as the Vega Therapeutics acquisition consume capital ahead of the cliff.

WHY IT MATTERS FOR THE S&P 500

Incyte is a small-weight health care constituent: rank #367 by weight at 0.03% as of Nov 4, 2026, and #46 in Health Care. It is the index's mid-cap biotech transition story — a single-franchise company proving, in real time, that its second act can outgrow its first before the patent clock runs out.

SOURCES & METHODOLOGY

Financials, segments, headquartersIncyte Corporation fiscal 2025 Form 10-K data (year ended December 31, 2025) and fourth-quarter/full-year 2025 results release; headquarters, CEO and products via the Form 10-K and company reporting
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 4, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$23.97B (Slickcharts, Nov 4, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

INCY

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號INCY
公司Incyte Corporation(Incyte)
GICS 板塊/行業醫療保健(XLV)/生物科技
標普500排名(按權重)#367 · 0.03%(Nov 4, 2026)
板塊內排名醫療保健 #46(共 60 家)(Nov 4, 2026)
總部美國特拉華州威爾明頓
成立1991年
執行長Bill Meury(總裁兼執行長,按 2026 年 2 月業績公布)
員工2,844 名全職員工
市值$23.97B(Nov 4, 2026)
SEC 申報EDGAR — CIK 0000879169

業務概覽

Incyte Corporation 是全球生物製藥公司,總部位於美國特拉華州威爾明頓,專注血液學與腫瘤學以及炎症與自身免疫疾病。公司成立於 1991 年,自行發現、開發並銷售專利藥物,透過自身業務及與 Novartis、Eli Lilly 等夥伴的合作,在美國、歐洲與日本銷售。

其一句話商業模式是:把 JAK 通路與靶向科學轉化為上市藥物,再把產品現金流再投資於橫跨血液學、腫瘤學與皮膚科的研發管線。旗艦產品為 Jakafi(ruxolitinib),用於骨髓纖維化、真性紅細胞增多症與移植物抗宿主病;增長引擎是以 Opzelura(ruxolitinib)乳膏為首的非 Jakafi 產品組合。

2025 財年總收入 51.41 億美元,增長 21%,其中淨產品收入 43.53 億美元,增長 20%。非 Jakafi 核心業務 2025 年增長 53% 至 12.63 億美元,Opzelura、治療慢性移植物抗宿主病的 Niktimvo(axatilimab-csfr)與 Monjuvi(tafasitamab)是增長最大的產品。

業務板塊

Jakafi(ruxolitinib)旗艦 JAK 抑制劑,用於骨髓纖維化、真性紅細胞增多症與移植物抗宿主病;美國以外與 Novartis 合作,是最大的單一產品。
Opzelura(ruxolitinib)乳膏外用 JAK 抑制劑,用於特應性皮炎與白癜風;是非 Jakafi 增長故事的核心動力,包括美國批准用於 2–11 歲兒童濕疹患者。
其他血液/腫瘤產品治療慢性移植物抗宿主病的 Niktimvo、治療復發或難治性瀰漫性大 B 細胞淋巴瘤的 Monjuvi,以及 Pemazyre 與 Iclusig;連同 Opzelura,非 Jakafi 核心業務 2025 年達 12.63 億美元,增長 53%。
里程碑、特許權使用費及其他收入合作里程碑與合約收入及特許權使用費——即 2025 年總收入 51.41 億美元與淨產品收入 43.53 億美元之間的差額。

歷史

年份里程碑
1991Incyte 在特拉華州威爾明頓成立為藥物發現公司。
2011Jakafi 成為公司的支柱產品(ruxolitinib,美國以外由 Novartis 合作開發)。
2014Hervé Hoppenot 自 2014 年起出任執行長,領導 Jakafi 的商業化時代。
2021Opzelura 乳膏上市,在血液學與腫瘤學之外開闢皮膚科業務。
2025總收入達 51.41 億美元,增長 21%;非 Jakafi 產品增長 53% 至 12.63 億美元,Bill Meury 在 2026 年 2 月業績公布中為總裁兼執行長。

競爭地位

  • Jakafi 深度:在罕見血癌領域擁有龐大而穩固的美國業務,2025 年指引評論中處方量增長仍為高單位數。
  • 分散化進行中:非 Jakafi 核心業務 2025 年增長 53%,預計 2026 年增長逾 30%,在 Jakafi 專利期限之前降低對單一產品的依賴。
  • 合作槓桿:Novartis(美國以外 Jakafi)、Lilly 等夥伴擴大覆蓋範圍,無須全面自建全球商業網絡。
  • 競爭對手:大型血液與腫瘤藥企及皮膚科對手,以及專利到期後的仿製藥。

財務快照

總收入$5.14B(FY2025 總收入)
營業利潤$1.51B(FY2025 營業利潤)
淨利潤$1.29B(FY2025 淨利潤)
稀釋 EPS$6.59(FY2025 稀釋 EPS)
來源:來源:Incyte Corporation 2025 財年 Form 10-K(截至 2025 年 12 月 31 日,2026 年 2 月 10 日提交)及 2025 年第四季與全年業績公布。精確數字:總收入 51.41 億美元;營業利潤 15.15 億美元;淨利潤 12.87 億美元;稀釋 EPS 6.59 美元;淨產品收入約 43.52 億美元(披露為 43.53 億美元)。2024 財年對比:總收入 42.41 億美元;淨利潤 0.33 億美元;稀釋 EPS 0.16 美元。

主要風險

  • Jakafi 集中與專利期限:旗艦產品面臨 2028 年專利到期,分散化須在仿製藥出現之前擴大規模。
  • 管線風險:血液學、腫瘤學與皮膚科候選藥物的臨床、監管與商業執行。
  • 定價與支付方壓力:專科藥定價、毛額轉淨額動態與藥物名錄准入影響實際收入。
  • 單一產品連帶影響:Jakafi 需求、競爭或安全性訊號仍會牽動集團表現。
  • 併購與資本配置:Vega Therapeutics 收購等交易在專利懸崖之前消耗資金。

對標普500的重要性

Incyte 是權重較小的醫療保健成分股:按權重排名 #367,權重 0.03%(以 2026 年 11 月 4 日為準),醫療保健板塊內排名 #46。它是指數中的中型生物科技轉型故事——一家單一業務公司正在實時證明,其第二幕可以在專利時鐘走完之前超越第一幕。

來源與方法

財務、板塊、總部Incyte Corporation 2025 財年 Form 10-K 數據(截至 2025 年 12 月 31 日)及 2025 年第四季與全年業績公布;總部、執行長與產品經 Form 10-K 及公司披露
指數權重與排名Slickcharts 標普 500 權重,Nov 4, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$23.97B(Slickcharts,Nov 4, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

INCY

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · INCY
Data as of Nov 4, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Tapestry, Inc. (TPR) — XLY Consumer Discretionary · S&P 500 Profile |泰佩思琦公司介紹Next · PulteGroup, Inc. (PHM) — XLY Consumer Discretionary · S&P 500 Profile |PulteGroup 公司介紹

Entered 2026-11-03 21:47 · updated 2026-11-14 23:39 · rev 7